CP-547632

A potent inhibitor of VEGFR2 and bFGF

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥862.00

690.00

- +
10mg

￥1525.00

1220.00

- +
25mg

￥3025.00

2420.00

- +
50mg

￥4800.00

3840.00

- +
100mg

￥8137.00

6510.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajcx13012
CAS: 252003-65-9
别名: 3-[(4-溴-2,6-二氟苄基)氧基]-5-[3-[4-(吡咯烷-1-基)丁基]脲基]异噻唑-4-甲酰胺
分子式: C20H24BrF2N5O3S
分子量: 532.4
纯度: >98%
溶解度: DMSO: ≥ 115 mg/mL (216.00 mM)
储存: Store at -20°C
库存: 现货

Background

CP 547,632 is an orally bioavailable and potent inhibitor of the receptor tyrosine kinases VEGF receptor 2 (VEGFR2) and basic fibroblast growth factor (bFGF) with IC₅₀ values of 11 and 9 nM, respectively, in an enzyme assay.¹ It is selective for VEGFR2 and bFGF over EGFR, PDGF receptor β (PDGFRβ), and related tyrosine kinases. CP 547,632 inhibits VEGFR2 autophosphorylation induced by VEGF in porcine aortic endothelial cells transfected with VEGFR2 (IC₅₀ = 6 nM) and in a xenograft mouse model using NIH3T3/H-Ras cells (EC₅₀ = 590 nM). It decreases angiogenesis induced by VEGF or bFGF and suppresses tumor growth in athymic mice.

1.Beebe, J.S., Jani, J.P., Knauth, E., et al.Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapyCancer Res.63(21)7301-7309(2003)